Raptiva Labeling Should Require Monitoring For Thrombocytopenia – Cmte.

Genentech/Xoma Raptiva labeling should require platelet count monitoring to minimize the risk of thrombocytopenia, FDA Dermatologic & Ophthalmic Drugs Advisory Committee recommended